Evolus reports Q1 EPS (30c), consensus (14c)

Reports Q1 revenue $68.5M, consensus $72.4M. U.S. tariffs on medical devices related to Evolysse “have been fully incorporated into 2025 guidance with no change.” “Coming off a record year, we enter 2025 with strong momentum,” said David Moatazedi, President and Chief Executive Officer of Evolus (EOLS). “In our final quarter as a single-product company, we gained meaningful market share to start the year and delivered 15.5% year-over-year growth, on top of an exceptionally strong prior-year quarter which had grown 42%. This growth is driven by sustained demand for Jeuveau(R) and an increase in engagement with Evolus’ superior value proposition. In April, we officially launched Evolysse(TM) in the U.S., and early feedback from customers has been overwhelmingly positive. Early metrics indicate strong interest and adoption, meaningfully outperforming the initial launch of Jeuveau(R) and several thousand customers already trialing the product. With increased Jeuveau(R) market share more than offsetting slower market growth, combined with the early success of Evolysse(TM), we are confident in reiterating our full-year 2025 revenue guidance of $345 million to $355 million and expect to achieve our sixth consecutive year of revenue growth above 30%.”